February 2026 in “Cureus” Recognizing and managing skin side effects from chemotherapy improves patient quality of life and treatment success.
February 2026 in “Clinical Cancer Research” Many Instagram posts about breast cancer symptoms are misleading and not created by healthcare professionals.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
January 2026 in “European Journal of Cancer Care” Social support improves empowerment and quality of life for breast cancer patients with hair loss.
January 2026 in “RSC Medicinal Chemistry” 2,5-DBH shows promise for improving drugs in cancer, brain disorders, and infections.
December 2025 in “Pharmaceutics” EV-based drug delivery shows promise but faces challenges in standardization and scalability.
September 2025 in “Cureus” Early recognition and multidisciplinary management are crucial for improving outcomes in Parry-Romberg syndrome.
September 2025 in “Cancer Innovation” Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.
December 2024 in “IntechOpen eBooks” Drug repurposing speeds up development, cuts costs, and uses known safe drugs, but faces challenges like regulations and patents.
Pomegranate is beneficial in various medical fields.
January 2024 in “Faculty of 1000 Research Ltd” Most pediatric cancer patients at Muhimbili National Hospital experienced adverse drug reactions during chemotherapy, highlighting the need for careful monitoring.
April 2023 in “International Journal of Medical Science and Clinical Research Studies” Accurate diagnosis of rare scalp cancer requires combining clinical and radiological information.
October 2022 in “Journal of Pharmaceutical Negative Results” Photobiomodulation therapy shows promise in treating various health conditions by using specific light wavelengths.
August 2018 in “SDÜ SAĞLIK BİLİMLERİ DERGİSİ” No method fully prevents hair loss from chemotherapy, but some methods can reduce it and improve quality of life.
May 2016 in “Journal of pediatric nursing” Lavender oil use in a child may be linked to early puberty signs and elevated tumor marker levels.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
June 2003 in “Clinical orthopaedics and related research” The man had a fungal infection in his knee, treated with surgery and antifungal medication.
2 citations
,
January 2017 in “Springer eBooks” The book is a detailed guide on children's skin disorders, their causes, and diagnosis, with many images for medical professionals.
30 citations
,
March 2007 in “Expert opinion on drug safety” Cetuximab often causes skin rashes, and managing these is important for cancer treatment.
28 citations
,
July 2017 in “Expert Review of Anticancer Therapy” Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
January 2021 in “Journal of the European Academy of Dermatology and Venereology” PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
1 citations
,
October 2006 in “Oncology times” Finasteride improves prostate cancer detection in PSA test.
1 citations
,
September 2005 in “Oncology times” Wearing a frozen glove during chemotherapy can reduce nail and skin problems but may not be comfortable for everyone.
1 citations
,
February 2002 in “Oncology Times” Intravenous arsenic is safe and effective for treating certain blood cancers.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
February 2020 in “Oncology Times” Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
October 2018 in “Oncology Times” Hair is important for aging and cancer treatment, affecting emotions, culture, and health.